Guardant Health Secures FDA Nod for HER2-Mutant NSCLC Diagnostic
PALO ALTO, Calif., June 11, 2026 Guardant Health announced that the U.S. Food and Drug Administration (FDA) has approved...
HERNEXEOS
Advertisement
Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...
Accent Therapeutics Advances ATX-295 at ASCO
LEXINGTON, Mass., May 21, 2026 Accent Therapeutics has announced the presentation of a Trial in Progress poster for its...
Boehringer Ingelheim Highlights Strong Oncology Advances at ASCO 2026
INGELHEIM, Germany & RIDGEFIELD, Conn., May 21, 2026 Boehringer Ingelheim has unveiled significant new oncology data at the 2026...
FDA Grants Breakthrough Therapy Designation to HERNEXEOS® for First-Line Treatment of HER2-Mutant Advanced NSCLC
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for HERNEXEOS®...
Advertisement
